The peptide GALA undergoes a conformational change to an amphipathic alpha-helix when the pH is reduced, inducing leakage of contents from vesicles. Leakage from neutral or negatively-charged vesicles at pH 5.0 was similar and could be adequately explained by a mathematical model which assumed that GALA becomes incorporated into the vesicle bilayer and irreversibly aggregates to form a pore consisting of M = 10 +/- 2 peptides. Increasing cholesterol content in the membranes resulted in reduced leakage, and increased reversibility of surface aggregation of the peptide. Employing fluorescently labelled peptides confirmed that the degree of reversibility of surface aggregation of GALA was significantly larger in cholesterol containing liposomes. Orientation of the peptide GALA in bilayers was determined by a bodipy-avidin/biotin binding assay. The peptide was labelled by biotin at the N- or C-terminus and bodipy-avidin molecules were added externally or were preencapsulated in the vesicles. The peptides are arranged in the pore perpendicularly to the membrane, such that 3/4 of the N-termini are on the internal side of the membrane. The pores are stable and persist for at least 10 min. When the peptides form an aggregate of size smaller than M, the orientation of the peptide is mostly parallel to the surface and the biotinylated peptide does not translocate. When a critical size of the aggregate is attained, a rearrangement of the peptide occurs, which amounts to rapid penetration and formation of a pore structure. Induction of fusion by peptides may be antagonistic to pore formation, the outcome being dependent on vesicle aggregation.

This review deals with modification of montmorillonite and other clay-minerals and clays by interacting them with organic cations, for producing slow release formulations of herbicides, and efficient removal of pollutants from water by filtration. Elaboration is on incorporating initially the organic cations in micelles and liposomes, then producing complexes denoted micelle- or liposome-clay nano-particles. The material characteristics (XRD, Freeze-fracture electron microscopy, adsorption) of the micelle– or liposome–clay complexes are different from those of a complex of the same composition (organo-clay), which is formed by interaction of monomers of the surfactant with the clay-mineral, or clay. The resulting complexes have a large surface area per weight; they include large hydrophobic parts and (in many cases) have excess of a positive charge. The organo-clays formed by preadsorbing organic cations with long alkyl chains were also addressed for adsorption and slow release of herbicides. Another examined approach includes “adsorptive” clays modified by small quaternary cations, in which the adsorbed organic cation may open the clay layers, and consequently yield a high exposure of the siloxane surface for adsorption of organic compounds. Small scale and field experiments demonstrated that slow release formulations of herbicides prepared by the new complexes enabled reduced contamination of ground water due to leaching, and exhibited enhanced herbicidal activity. Pollutants removed efficiently from water by the new complexes include (i) hydrophobic and anionic organic molecules, such as herbicides, dissolved organic matter; pharmaceuticals, such as antibiotics and non-steroidal drugs; (ii) inorganic anions, e.g., perchlorate and (iii) microorganisms, such as bacteria, including cyanobacteria (and their toxins). Model calculations of adsorption and kinetics of filtration, and estimation of capacities accompany the survey of results and their discussion.

Objective: To assess the real-world use, clinical outcomes, and adherence to novel P2Y12 inhibitors. Methods: We evaluated 1,093 consecutive acute myocardial infarction patients undergoing a percutaneous intervention. Patients were derived from a prospective, multicenter, nationwide registry and were followed for 30 days; 381 patients (35%) received clopidogrel, 468 (43%) received prasugrel, and 244 (22%) received ticagrelor. Patients treated with clopidogrel were older and more likely to suffer from chronic renal failure and stroke and/or present with non-ST-elevation myocardial infarction (NSTEMI) (p < 0.01 for all). Independent predictors of undertreatment with novel P2Y12 inhibitors included: older age (OR 0.17; 95% CI 0.1-0.27, p < 0.0001), a prior stroke (OR 0.41; 95% CI 0.2-0.68, p = 0.008), and NSTEMI (OR 0.37; 95% CI 0.26-0.54, p < 0.0001). Results: Novel P2Y12 inhibitors were associated with a lower incidence of cardiovascular events, major bleeding, and/or death (7.6 vs.11%, HR 0.67; 95% CI 0.43-1, p = 0.05). However, after a multivariate analysis this trend was not statistically significant. Patients discharged with ticagrelor versus thienopyridines demonstrated a higher rate of crossover to other P2Y12 inhibitors (11 vs. 5%, p = 0.03). Conclusions: In a real-world cohort, there was an underutilization of novel P2Y12 inhibitors which was more pronounced in higher-risk subsets that might benefit from novel P2Y12 inhibitors at least as much as other patients.